Frontier IP Group EBIT per Share
The EBIT per Share of Frontier IP Group (FIPP.L) as of Aug 13, 2026 is -0.05 GBP. In the previous year, EBIT per Share was -0.06 GBP — a change of -10.06% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.05GBP
YoY
-10.06%
Last updated:
EBIT per Share of Frontier IP Group is 2026 -0.05 GBP. EBIT per Share of Frontier IP Group was 2025 -0.06 GBP. It decreases by -10.06% higher compared to the previous year.
Access this data via the Eulerpool API
Frontier IP Group Stock analysis
What does Frontier IP Group do? The Frontier IP Group PLC is a British company specializing in technology investment and listed on the London Stock Exchange. The company was founded in 2000 and is headquartered in London. Frontier IP invests in promising technology companies and supports them in the development of their products.
The business model of Frontier IP is based on investing in promising companies to further develop their technology and business areas. The company has extensive experience in technology development and marketing and works closely with its portfolio companies.
Currently, Frontier IP is investing in numerous companies in various sectors such as biotechnology, artificial intelligence, environmental technology, and agricultural technology. The investments range from start-up companies to established companies already present in the market. Each company in which Frontier IP is involved has unique technologies and innovations in the field of research and development, which have a significant impact on their respective markets.
The products and services offered by Frontier IP and its portfolio companies include various biotechnological products and procedures, including antibodies, vaccines, and cell therapies. Frontier IP also invests in companies that develop advanced sensor technologies, robotics, and AI systems that can contribute to the automation of various industries.
One example is The Vaccine Group. The Vaccine Group was founded in 2003 as a spin-off from the University of Plymouth and is a leading developer of novel human vaccines. The focus is on developing vaccines against infectious diseases classified as special challenges by the World Health Organization (WHO).
Another example is Exscientia. Exscientia specializes in applied AI technology to accelerate drug discovery and development. The company has already achieved several groundbreaking successes and collaborates with leading pharmaceutical companies to develop innovative formulations with shorter development times.
Frontier IP has also invested in Cambridge Raman Imaging Limited, which has developed an innovative method for high-speed imaging of cells and biological samples. This technology can be used in medical diagnostics or in the development of new drugs.
Overall, Frontier IP Group is a significant company in the technology and investment industry. The company specializes in investing in promising technology companies and has extensive expertise in technology development and marketing. Through its investments, Frontier IP has already developed innovative products and services that have a significant impact on various industries and markets and will continue to play an important role in the future. Frontier IP Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Frontier IP Group stock
EBIT per Share of Frontier IP Group is -0.05 GBP in 2026.
EBIT per Share of Frontier IP Group changed from -0.06 GBP to -0.05 GBP, representing a -10.06% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Frontier IP Group since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Frontier IP Group
All Key Metrics — Frontier IP Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth